2011 News Releases

iCo Therapeutics CMO to Present at The Drug Repositioning Conference

For Immediate Release                                                                                   July 12, 2011

VANCOUVER, Canada - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that Dr. Peter Hnik, iCo's Chief Medical Officer, will present at the Drug Repositioning Conference in San Francisco, CA.  Dr. Hnik's presentation, "Repositioning a Monoclonal Antibody for Niche Markets" will be a case study focused on Bertilimumab, (iCo-008), the company's anti-eotaxin-1 human monoclonal antibody with 126-patient clinical history.  Dr. Hnik's presentation will take place at 2:30 pm on July 14, 2011.  iCo licensed Bertilimumab systemic rights to IMMUNE Pharmaceuticals in June 2011.  iCo retained rights to all ophthalmic indications and plans to develop Bertilimumab for severe ocular allergies and age-related macular degeneration.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.   iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase 2 for the treatment of DME, iCo-008 (Bertilimumab); a product with Phase 2 clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.  iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration.   iCo was awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada in 2010 and is a Canada's Top 10™ Competition winner.  iCo trades on the TSX Venture Exchange under the symbol "ICO".  For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

 

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Copyright 2015 ICO Therapeutics | Disclaimer